iPremom's Circulating RNA Test Reads the Preeclampsia Signal Five Months Early

For a condition that can escalate from a routine prenatal visit to an ICU admission in a matter of days, the standard diagnostic tools for preeclampsia are frustratingly blunt. Doctors rely on blood pressure readings and protein in the urine, signs that typically appear only after the disease has taken hold. A Spanish startup, iPremom, is betting that the answer lies not in these late-stage clinical markers, but in the molecular whispers of circulating RNA (cfRNA) present in a mother’s blood during the first trimester. Their work suggests a simple blood draw could flag high-risk pregnancies months before symptoms manifest, a shift that would reframe preeclampsia from a reactive crisis to a manageable, monitored condition.

A bet on first-trimester molecular signatures

iPremom’s core proposition is a molecular blood test designed to detect the risk of preeclampsia and other pregnancy complications long before traditional diagnosis. The company’s technology hinges on analyzing cfRNA profiles, fragments of genetic material shed by the placenta and maternal tissues into the bloodstream. By applying high-throughput transcriptomics and machine learning to these profiles, iPremom aims to identify specific RNA signatures associated with the onset of preeclampsia [iPremom]. The clinical rationale is humane: earlier risk stratification allows for closer monitoring, timely intervention with medications like low-dose aspirin, and better preparation for potential complications, all of which can improve outcomes for both mother and child.

The scientific foundation for this approach was laid in the large-scale “PREMOM” study (NCT04990141), a prospective clinical trial that enrolled 9,586 pregnant women across fourteen tertiary hospitals in Spain [Nature Communications]. According to the company, this study demonstrated that a first-trimester blood test could accurately identify women at risk of developing preeclampsia approximately five months before clinical diagnosis [EurekAlert!, Jun 2025]. The research further indicated the test could differentiate between subtypes of preeclampsia and evaluate organ damage, offering prognostic insights [Nature Communications].

The team behind the transcriptomics

While iPremom maintains a low public profile regarding its corporate structure, the scientific leadership anchoring its work is well-established. The effort is closely associated with Prof. Carlos Simón, a reproductive medicine specialist and serial entrepreneur whose career lends significant credibility to the venture. Simón, a founder and former Chief Science Officer of the reproductive diagnostics firm Igenomix, brings over three decades of clinical and research experience to the project [Carlos Simón]. The company’s scientific manager is Dr. Aymara Mas, a senior principal investigator at the Carlos Simón Foundation, and its day-to-day operations are led by CEO Alfonso Sánchez Córcoles [LinkedIn]. This blend of deep scientific expertise and operational leadership suggests a team structured to navigate the complex path from biomarker discovery to regulated diagnostic.

Role	Name	Background
Scientific Lead	Prof. Carlos Simón	Reproductive endocrinology pioneer, founder of Igenomix, over 30 patents [Carlos Simón].
Scientific Manager	Dr. Aymara Mas	Senior principal investigator, Carlos Simón Foundation R&D [Carlos Simon Foundation].
CEO	Alfonso Sánchez Córcoles	Leads company operations [LinkedIn].

The path to the clinic and the counter-bets

The company has raised a modest seed round of approximately $199,000, according to one database [Seedtable]. For a diagnostic startup facing the costly gauntlet of clinical validation and regulatory clearance, this is a slender war chest. The next twelve months are therefore critical. iPremom has signaled that its cfRNA-based screening could become available in clinical practice within the next year [Inside Precision Medicine]. Achieving this will require not just continued scientific validation, but also navigating the European Union’s In Vitro Diagnostic Regulation (IVDR) or pursuing FDA clearance, processes that demand robust clinical data and manufacturing quality systems.

The competitive landscape for preeclampsia prediction is not empty, and iPremom’s approach faces several counter-bets. Other companies and research groups are exploring different biomarker strategies, from protein ratios like sFlt-1/PlGF to metabolomic profiles. iPremom’s specific wedge is its focus on first-trimester cfRNA, a potentially earlier signal than protein biomarkers that often rise later in pregnancy. The risks it must navigate are characteristic of the diagnostics space:

• Regulatory burden. Bringing a novel molecular test to market in Europe or the U.S. is a multi-year, capital-intensive process with no guaranteed outcome.
• Commercial adoption. Even with a CE mark or FDA clearance, convincing obstetric practices and healthcare systems to adopt and reimburse a new test requires proven clinical utility and cost-effectiveness.
• Scientific validation. While the PREMOM study results are promising, independent replication and publication in peer-reviewed journals will be necessary for broad clinical acceptance.

For the population it serves,pregnant individuals, particularly those with risk factors like a history of hypertension, diabetes, or prior preeclampsia,the standard of care today is largely watchful waiting. Routine prenatal visits monitor blood pressure and urine protein, but these are lagging indicators. Diagnosis often comes late, leading to rushed decisions about early delivery, the only definitive “cure” for preeclampsia, which carries its own risks for the newborn. A tool that reliably shifts the timeline from reaction to prevention would represent a fundamental change in obstetric practice, turning a dangerous complication into a condition that can be managed with foresight.

Sources

1. [iPremom] Protecting the lives of mothers and children | https://ipremom.com/
2. [Nature Communications] Research on cfRNA profiles for preeclampsia | https://www.nature.com/articles/s41467-024-48904-y
3. [EurekAlert!, Jun 2025] Simple blood test identifies preeclampsia risk five months early | https://www.eurekalert.org/news-releases/1049255
4. [Inside Precision Medicine] iPremom test could be available within a year | https://www.insideprecisionmedicine.com/news-and-features/simple-blood-test-could-predict-preeclampsia-five-months-before-diagnosis/
5. [Carlos Simón] Bio of Prof. Carlos Simón | https://carlos-simon.com/about-me/bio/
6. [Carlos Simon Foundation] Team page listing Dr. Aymara Mas | https://carlossimonfoundation.com/team/
7. [LinkedIn] iPremom company page | https://es.linkedin.com/company/ipremom
8. [Seedtable] iPremom listed among Spanish biotech startups | https://www.seedtable.com/best-biotech-startups-in-spain